(Q38454062)

English

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).

scientific article published on 23 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). (English)

1 reference

Europe PubMed Central

3 September 2017

0 references

0 references

Crohn's disease

1 reference

based on heuristic

inferred from title

object named as

Bettina E Hansen

2

0 references

author name string

Pieter Dewint

1

1 reference

Europe PubMed Central

3 September 2017

Elke Verhey

3

1 reference

Europe PubMed Central

3 September 2017

Bas Oldenburg

4

1 reference

Europe PubMed Central

3 September 2017

Daniel W Hommes

5

1 reference

Europe PubMed Central

3 September 2017

Marieke Pierik

6

1 reference

Europe PubMed Central

3 September 2017

Cyriel I J Ponsioen

7

1 reference

Europe PubMed Central

3 September 2017

Hendrik M van Dullemen

8

1 reference

Europe PubMed Central

3 September 2017

Maurice Russel

9

1 reference

Europe PubMed Central

3 September 2017

Ad A van Bodegraven

10

1 reference

Europe PubMed Central

3 September 2017

C Janneke van der Woude

11

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

23 March 2013

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

63

1 reference

Europe PubMed Central

3 September 2017

2

1 reference

Europe PubMed Central

3 September 2017

292-299

1 reference

Europe PubMed Central

3 September 2017

Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Diagnosis and treatment of perianal fistulas in Crohn disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Adalimumab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Preliminary study of ciprofloxacin in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Early stopping of randomized clinical trials for overt efficacy is problematic

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Systematic review: the management of pouchitis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-304488

21 January 2018

Identifiers

10.1136/GUTJNL-2013-304488

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38454062&oldid=1520579342"